Top Markets
Coin of the day
Novartis AG Novartis AG

Novartis AG

NOVN
Peringkat dalam Saham #57
Novartis AG researches, develops, manufactures, distributes, markets, and sells... Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD). It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for the treatment of allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Still’s disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and other types of functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma for the treatment of genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran), a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.
Harga Saham
$149.90
Terakhir disinkronkan: 2026-09-18
Kapitalisasi Pasar
$284.92B
Perubahan (1 hari)
-0.66%
Perubahan (1 tahun)
21.93%
Negara
CH
Perdagangan Novartis AG (NOVN)

Kategori

EPS untuk Novartis AG (NOVN)
EPS per December 2025 TTM: $7.19
Menurut laporan keuangan terbaru dan harga saham Novartis AG, EPS perusahaan saat ini (TTM) adalah $7.19. Pada akhir 2026, perusahaan memiliki EPS sebesar 0 sama dengan EPS tahun 2026 sebesar 0.
Riwayat EPS untuk Novartis AG dari 2026 hingga 2026
EPS di akhir setiap tahun
Tahun EPS Mengubah
Tidak cukup data untuk tanggal yang disediakan.
EPS untuk perusahaan sejenis atau pesaing
Perusahaan EPS Perbedaan EPS Negara
$29.85 315.16%
US
$8.65 20.31%
US
$3.55 -50.63%
US
$20.39 183.57%
CH
$1.26 -82.48%
US